Screening/Prevention
Diagnostic Test Approved for Differentiating Between Types of Lung Cancer
(07/23/2008)
A diagnostic test using MicroRNA technology has received regulatory approval to differentiate between the two main types of non–small cell lung cancer: squamous and non-squamous cell. These results were recently released in a press release by Rosetta Genomics Ltd.
Women Smokers Not at Greater Risk for Lung Cancer than Male Smokers
(07/07/2008)
Women smokers may not be at greater risk for lung cancer than their male counterparts. These results were recently published in Lancet Oncology.
Blood Test Shows Promise for Early Detection of Lung Cancer
(06/05/2008)
According to the results of a study presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), an experimental blood test may eventually allow for earlier detection of lung cancer in smokers.
Hormone Therapy Increases Risk for Breast and Lung Cancers
(03/05/2008)
Hormone therapy appears to increase the risk of breast cancer as well as lung cancer among postmenopausal women. These results were recently published in the Journal of the American Medical Association.
Minimally Invasive Endoscopic Procedure Shows Promise for Detecting Lung Cancer
(02/08/2008)
Use of a minimally invasive technique called endoscopy to detect lung cancer may be more effective than more complicated and invasive standard procedures. These findings were recently published in the Journal of the American Medical Association.
More...
Stages I-IIIA
Radiofrequency Ablation Effective for Primary Lung Tumors and Lung Metastases from Other Cancers
(07/30/2008)
The use of radiofrequency ablation for the treatment of lung cancer and lung metastases from breast, colon, and prostate cancers and melanoma is effective and safe for some patients. These results were recently published in the Lancet Oncology.
Addition of Preoperative Radiation to Chemotherapy Does Not Improve Survival in Stage III Non–Small Cell Lung Cancer
(07/07/2008)
The addition of radiation to chemotherapy prior to surgery does not appear to improve survival compared with preoperative chemotherapy alone for patients with Stage III non–small cell lung cancer (NSCLC). The results of this trial were recently published in Lancet Oncology.
Continued Treatment with Alimta® Delays Progression of Non–Small Cell Lung Cancer
(05/23/2008)
Treatment with the chemotherapy agent Alimta® (pemetrexed) following initial chemotherapy significantly delays disease progression in non–small cell lung cancer. These results were recently reported by the American Society of Clinical Oncology (ASCO) and will be presented at their upcoming annual meeting.
Avastin® plus Chemotherapy Shows Promise for Treatment of Non–Small Cell Lung Cancer
(04/30/2008)
The combination of Avastin® (bevacizumab), Gemzar® (gemcitabine), and Platinol® (cisplatin) prolonged progression-free survival when compared with chemotherapy alone among patients with non-small cell lung cancer. These results were recently reported by the pharmaceutical company Genentech.
Surgery Effective in Elderly Patients with Lung Cancer
(04/21/2008)
Surgery for the treatment of lung cancer in patients 80 years and older is a safe and effective treatment approach for those who are eligible. These results were recently presented at the American Association for Cancer Research 2008 Annual Meeting.
More...
Stages IIIB-IV
Measuring EGFR from Cancer Cells in Blood Can Monitor Treatment Effectiveness in Lung Cancer
(07/07/2008)
Measuring changes in cancer cells through a microchip from blood samples may provide a way to monitor treatment effectiveness among patients with advanced non–small cell lung cancer (NSCLC). These results were recently published in the New England Journal of Medicine.
Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers
(06/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.
Erbitux® plus Chemotherapy Modestly Improves Survival in Advanced Non–Small Cell Lung Cancer
(06/02/2008)
According to results of a Phase III clinical trial, initial treatment of advanced non–small cell lung cancer with the targeted therapy Erbitux® (cetuximab) plus chemotherapy improves overall survival by roughly five weeks compared with chemotherapy alone. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Continued Treatment with Alimta® Delays Progression of Non–Small Cell Lung Cancer
(05/23/2008)
Treatment with the chemotherapy agent Alimta® (pemetrexed) following initial chemotherapy significantly delays disease progression in non–small cell lung cancer. These results were recently reported by the American Society of Clinical Oncology (ASCO) and will be presented at their upcoming annual meeting.
Avastin® plus Chemotherapy Shows Promise for Treatment of Non–Small Cell Lung Cancer
(04/30/2008)
The combination of Avastin® (bevacizumab), Gemzar® (gemcitabine), and Platinol® (cisplatin) prolonged progression-free survival when compared with chemotherapy alone among patients with non-small cell lung cancer. These results were recently reported by the pharmaceutical company Genentech.
More...
Recurrent
Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers
(06/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.
Nexavar® Improves Survival in Recurrent Non–Small Cell Lung Cancer
(06/06/2008)
Patients with recurrent non–small cell lung cancer (NSCLC) who were treated with Nexavar® (sorafenib) experienced a delay in disease progression and a possible improvement in overall survival. These findings were reported at the 2008 annual meeting of the American Society of Clinical Oncology.
Addition of Avastin® Superior to Chemotherapy Alone in Lung Cancer
(10/15/2007)
According to an article recently published in the Journal of Clinical Oncology, the addition of Avastin® (bevacizumab) to Tarceva® (erlotinib) or to chemotherapy improves survival compared with chemotherapy alone in the treatment of recurrent non–small cell lung cancer.
Iressa® and Taxotere® Provide Same Survival in Recurrent Non–Small Cell Lung Cancer
(09/06/2007)
According to results presented at the 2007 annual International Association for the Study of Lung Cancer (IASLC), Iressa® (gefitinib) may provide equal outcomes with an improved quality of life compared to Taxotere® (docetaxel) for the treatment of recurrent non–small cell lung cancer among patients who have received one prior treatment regimen.
Ixabepilone Has Anticancer Activity in Recurrent Non–Small Cell Lung Cancer
(08/09/2007)
According to an article recently published in the Journal of Clinical Oncology, the agent ixabepilone provides significant anticancer activity in the treatment of non–small cell lung cancer among patients who have experienced cancer progression following a platinum-based chemotherapy regimen.
More...